Brian Davis - Strongbridge Biopharma CFO
CFO
Mr. A. Brian Davis is Chief Financial Officer of the company. since March 2015. Prior to joining Strongbridge, Mr. Davis served as Senior Vice President and Chief Financial Officer at Tengion, Inc., a publicly traded regenerative medicine company, from August 2010 to December 2014. In December 2014, Tengion, Inc. filed a petition for relief under Chapter 7 of Title 11 of the United States Bankruptcy Code. From 2009 to July 2010, Mr. Davis served in a consulting capacity as Chief Financial Officer of Neose Technologies, Inc., a biopharmaceutical company. Mr. Davis worked at Neose Technologies, Inc. from 1994 to 2009, where he held several positions of increasing responsibility, including Senior Vice President and Chief Financial Officer since 2015.
| Age | 47 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 610 254 9200 |
| Web | http://www.strongbridgebio.com |
Strongbridge Biopharma Management Efficiency
The company has return on total asset (ROA) of (27.5) % which means that it has lost $27.5 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (87.06) %, meaning that it created substantial loss on money invested by shareholders. Strongbridge Biopharma's management efficiency ratios could be used to measure how well Strongbridge Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 18.68 M in liabilities with Debt to Equity (D/E) ratio of 0.42, which is about average as compared to similar companies. Strongbridge Biopharma has a current ratio of 2.94, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Strongbridge Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Strongbridge Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Strongbridge Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Strongbridge to invest in growth at high rates of return. When we think about Strongbridge Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 7 records | CFO Age | ||
| Katherine Scherping | National CineMedia | 58 | |
| Jeffrey Cabot | National CineMedia | 46 | |
| Elissa Brown | Perseus Mining Limited | N/A | |
| Andrew Davis | Emerson Radio | 46 | |
| Eugene Bullis | The Hanover Insurance | 69 | |
| Terry Eleftheriou | Employers Holdings | 54 | |
| David Oddo | National CineMedia | 47 | |
Management Performance
| Return On Equity | -87.06 | |||
| Return On Asset | -27.5 |
Strongbridge Biopharma Leadership Team
Elected by the shareholders, the Strongbridge Biopharma's board of directors comprises two types of representatives: Strongbridge Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Strongbridge. The board's role is to monitor Strongbridge Biopharma's management team and ensure that shareholders' interests are well served. Strongbridge Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Strongbridge Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Pauls, CEO and President and Director | ||
| Brian Davis, CFO | ||
| Richard Kollender, Director | ||
| Davis, CFO | ||
| Robert Lutz, Chief Bus. Officer | ||
| Garheng Kong, Director | ||
| John Johnson, Chairman of the Board | ||
| Marten Steen, Director | ||
| Stephen Long, Chief Legal Officer | ||
| Ruth MD, Chief Medical Officer | ||
| Ruth ThieroffEkerdt, Chief Medical Officer | ||
| Marcy Nanus, Vice President - Corporate Affairs | ||
| Hilde Steineger, Director | ||
| Per MD, Founder and Sr. Clinical Advisor | ||
| Scott Wilhoit, Chief Commercial Officer |
Strongbridge Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Strongbridge Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -87.06 | |||
| Return On Asset | -27.5 | |||
| Profit Margin | (115.67) % | |||
| Operating Margin | (123.23) % | |||
| Current Valuation | 85.82 M | |||
| Shares Outstanding | 67.77 M | |||
| Shares Owned By Insiders | 13.64 % | |||
| Shares Owned By Institutions | 67.14 % | |||
| Number Of Shares Shorted | 570.8 K | |||
| Price To Earning | 5.54 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Strongbridge Biopharma information on this page should be used as a complementary analysis to other Strongbridge Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Strongbridge Stock
If you are still planning to invest in Strongbridge Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Strongbridge Biopharma's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |